Selected research
Market Structure
Global Respiratory Syncytial Virus Vaccine for Children Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Respiratory Syncytial Virus Vaccine for Children market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Respiratory Syncytial Virus Vaccine for Children is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Respiratory Syncytial Virus Vaccine for Children is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Respiratory Syncytial Virus Vaccine for Children is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Respiratory Syncytial Virus Vaccine for Children is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Respiratory Syncytial Virus Vaccine for Children include Clover Biopharma, Advaccine, Wits Health Consortium (Pty) Ltd, Sanofi, Pfizer, Novavax, Moderna, Meissa and Codagenix, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Respiratory Syncytial Virus Vaccine for Children market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Respiratory Syncytial Virus Vaccine for Children and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Respiratory Syncytial Virus Vaccine for Children sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Respiratory Syncytial Virus Vaccine for Children market size, projected growth trends, production technologies, key applications, and end-use industries.
Respiratory Syncytial Virus Vaccine for Children Segment by Company
Clover Biopharma
Advaccine
Wits Health Consortium (Pty) Ltd
Sanofi
Pfizer
Novavax
Moderna
Meissa
Codagenix
Blue Lake Biotechnology
Respiratory Syncytial Virus Vaccine for Children Segment by Type
Recombinant Protein Vaccine
Nucleic Acid Vaccine
Others
Respiratory Syncytial Virus Vaccine for Children Segment by Application
Hospital
Centers for Disease Control and Prevention
Others
Respiratory Syncytial Virus Vaccine for Children Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Respiratory Syncytial Virus Vaccine for Children market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Respiratory Syncytial Virus Vaccine for Children and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Respiratory Syncytial Virus Vaccine for Children.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Respiratory Syncytial Virus Vaccine for Children market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Respiratory Syncytial Virus Vaccine for Children manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Respiratory Syncytial Virus Vaccine for Children in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Respiratory Syncytial Virus Vaccine for Children in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Recombinant Protein Vaccine
- Nucleic Acid Vaccine
- Others
Applications
- Hospital
- Centers for Disease Control and Prevention
- Others
Companies covered
- Clover Biopharma
- Advaccine
- Wits Health Consortium (Pty) Ltd
- Sanofi
- Pfizer
- Novavax
- Moderna
- Meissa
- Codagenix
- Blue Lake Biotechnology
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Respiratory Syncytial Virus Vaccine for Children Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Respiratory Syncytial Virus Vaccine for Children Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Respiratory Syncytial Virus Vaccine for Children Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Respiratory Syncytial Virus Vaccine for Children Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Respiratory Syncytial Virus Vaccine for Children Market Dynamics
- 2.1 Respiratory Syncytial Virus Vaccine for Children Industry Trends
- 2.2 Respiratory Syncytial Virus Vaccine for Children Industry Drivers
- 2.3 Respiratory Syncytial Virus Vaccine for Children Industry Opportunities and Challenges
- 2.4 Respiratory Syncytial Virus Vaccine for Children Industry Restraints
3 Respiratory Syncytial Virus Vaccine for Children Market by Manufacturers
- 3.1 Global Respiratory Syncytial Virus Vaccine for Children Revenue by Manufacturers (2021-2026)
- 3.2 Global Respiratory Syncytial Virus Vaccine for Children Sales by Manufacturers (2021-2026)
- 3.3 Global Respiratory Syncytial Virus Vaccine for Children Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Respiratory Syncytial Virus Vaccine for Children Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Respiratory Syncytial Virus Vaccine for Children Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Respiratory Syncytial Virus Vaccine for Children Manufacturers, Product Type & Application
- 3.7 Global Respiratory Syncytial Virus Vaccine for Children Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Respiratory Syncytial Virus Vaccine for Children Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Respiratory Syncytial Virus Vaccine for Children Players Market Share by Revenue in 2025
- 3.8.3 2025 Respiratory Syncytial Virus Vaccine for Children Tier 1, Tier 2, and Tier 3
4 Respiratory Syncytial Virus Vaccine for Children Market by Type
- 4.1 Respiratory Syncytial Virus Vaccine for Children Type Introduction
- 4.1.1 Recombinant Protein Vaccine
- 4.1.2 Nucleic Acid Vaccine
- 4.1.3 Others
- 4.2 Global Respiratory Syncytial Virus Vaccine for Children Sales by Type
- 4.2.1 Global Respiratory Syncytial Virus Vaccine for Children Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Respiratory Syncytial Virus Vaccine for Children Sales by Type (2021-2032)
- 4.2.3 Global Respiratory Syncytial Virus Vaccine for Children Sales Market Share by Type (2021-2032)
- 4.3 Global Respiratory Syncytial Virus Vaccine for Children Revenue by Type
- 4.3.1 Global Respiratory Syncytial Virus Vaccine for Children Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Respiratory Syncytial Virus Vaccine for Children Revenue by Type (2021-2032)
- 4.3.3 Global Respiratory Syncytial Virus Vaccine for Children Revenue Market Share by Type (2021-2032)
5 Respiratory Syncytial Virus Vaccine for Children Market by Application
- 5.1 Respiratory Syncytial Virus Vaccine for Children Application Introduction
- 5.1.1 Hospital
- 5.1.2 Centers for Disease Control and Prevention
- 5.1.3 Others
- 5.2 Global Respiratory Syncytial Virus Vaccine for Children Sales by Application
- 5.2.1 Global Respiratory Syncytial Virus Vaccine for Children Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Respiratory Syncytial Virus Vaccine for Children Sales by Application (2021-2032)
- 5.2.3 Global Respiratory Syncytial Virus Vaccine for Children Sales Market Share by Application (2021-2032)
- 5.3 Global Respiratory Syncytial Virus Vaccine for Children Revenue by Application
- 5.3.1 Global Respiratory Syncytial Virus Vaccine for Children Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Respiratory Syncytial Virus Vaccine for Children Revenue by Application (2021-2032)
- 5.3.3 Global Respiratory Syncytial Virus Vaccine for Children Revenue Market Share by Application (2021-2032)
6 Global Respiratory Syncytial Virus Vaccine for Children Sales by Region
- 6.1 Global Respiratory Syncytial Virus Vaccine for Children Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Respiratory Syncytial Virus Vaccine for Children Sales by Region (2021-2032)
- 6.2.1 Global Respiratory Syncytial Virus Vaccine for Children Sales by Region (2021-2026)
- 6.2.2 Global Respiratory Syncytial Virus Vaccine for Children Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Respiratory Syncytial Virus Vaccine for Children Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Respiratory Syncytial Virus Vaccine for Children Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Respiratory Syncytial Virus Vaccine for Children Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Respiratory Syncytial Virus Vaccine for Children Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Respiratory Syncytial Virus Vaccine for Children Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Respiratory Syncytial Virus Vaccine for Children Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Respiratory Syncytial Virus Vaccine for Children Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Respiratory Syncytial Virus Vaccine for Children Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Respiratory Syncytial Virus Vaccine for Children Revenue by Region
- 7.1 Global Respiratory Syncytial Virus Vaccine for Children Revenue by Region
- 7.1.1 Global Respiratory Syncytial Virus Vaccine for Children Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Respiratory Syncytial Virus Vaccine for Children Revenue by Region (2021-2026)
- 7.1.3 Global Respiratory Syncytial Virus Vaccine for Children Revenue by Region (2027-2032)
- 7.1.4 Global Respiratory Syncytial Virus Vaccine for Children Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Respiratory Syncytial Virus Vaccine for Children Revenue (2021-2032)
- 7.2.2 North America Respiratory Syncytial Virus Vaccine for Children Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Respiratory Syncytial Virus Vaccine for Children Revenue (2021-2032)
- 7.3.2 Europe Respiratory Syncytial Virus Vaccine for Children Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Respiratory Syncytial Virus Vaccine for Children Revenue (2021-2032)
- 7.4.2 Asia-Pacific Respiratory Syncytial Virus Vaccine for Children Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Respiratory Syncytial Virus Vaccine for Children Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Respiratory Syncytial Virus Vaccine for Children Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Clover Biopharma
- 8.1.1 Clover Biopharma Company Information
- 8.1.2 Clover Biopharma Business Overview
- 8.1.3 Clover Biopharma Respiratory Syncytial Virus Vaccine for Children Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Clover Biopharma Respiratory Syncytial Virus Vaccine for Children Product Portfolio
- 8.1.5 Clover Biopharma Recent Developments
- 8.2 Advaccine
- 8.2.1 Advaccine Company Information
- 8.2.2 Advaccine Business Overview
- 8.2.3 Advaccine Respiratory Syncytial Virus Vaccine for Children Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 Advaccine Respiratory Syncytial Virus Vaccine for Children Product Portfolio
- 8.2.5 Advaccine Recent Developments
- 8.3 Wits Health Consortium (Pty) Ltd
- 8.3.1 Wits Health Consortium (Pty) Ltd Company Information
- 8.3.2 Wits Health Consortium (Pty) Ltd Business Overview
- 8.3.3 Wits Health Consortium (Pty) Ltd Respiratory Syncytial Virus Vaccine for Children Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Wits Health Consortium (Pty) Ltd Respiratory Syncytial Virus Vaccine for Children Product Portfolio
- 8.3.5 Wits Health Consortium (Pty) Ltd Recent Developments
- 8.4 Sanofi
- 8.4.1 Sanofi Company Information
- 8.4.2 Sanofi Business Overview
- 8.4.3 Sanofi Respiratory Syncytial Virus Vaccine for Children Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Sanofi Respiratory Syncytial Virus Vaccine for Children Product Portfolio
- 8.4.5 Sanofi Recent Developments
- 8.5 Pfizer
- 8.5.1 Pfizer Company Information
- 8.5.2 Pfizer Business Overview
- 8.5.3 Pfizer Respiratory Syncytial Virus Vaccine for Children Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Pfizer Respiratory Syncytial Virus Vaccine for Children Product Portfolio
- 8.5.5 Pfizer Recent Developments
- 8.6 Novavax
- 8.6.1 Novavax Company Information
- 8.6.2 Novavax Business Overview
- 8.6.3 Novavax Respiratory Syncytial Virus Vaccine for Children Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Novavax Respiratory Syncytial Virus Vaccine for Children Product Portfolio
- 8.6.5 Novavax Recent Developments
- 8.7 Moderna
- 8.7.1 Moderna Company Information
- 8.7.2 Moderna Business Overview
- 8.7.3 Moderna Respiratory Syncytial Virus Vaccine for Children Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Moderna Respiratory Syncytial Virus Vaccine for Children Product Portfolio
- 8.7.5 Moderna Recent Developments
- 8.8 Meissa
- 8.8.1 Meissa Company Information
- 8.8.2 Meissa Business Overview
- 8.8.3 Meissa Respiratory Syncytial Virus Vaccine for Children Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Meissa Respiratory Syncytial Virus Vaccine for Children Product Portfolio
- 8.8.5 Meissa Recent Developments
- 8.9 Codagenix
- 8.9.1 Codagenix Company Information
- 8.9.2 Codagenix Business Overview
- 8.9.3 Codagenix Respiratory Syncytial Virus Vaccine for Children Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 Codagenix Respiratory Syncytial Virus Vaccine for Children Product Portfolio
- 8.9.5 Codagenix Recent Developments
- 8.10 Blue Lake Biotechnology
- 8.10.1 Blue Lake Biotechnology Company Information
- 8.10.2 Blue Lake Biotechnology Business Overview
- 8.10.3 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for Children Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for Children Product Portfolio
- 8.10.5 Blue Lake Biotechnology Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Respiratory Syncytial Virus Vaccine for Children Value Chain Analysis
- 9.1.1 Respiratory Syncytial Virus Vaccine for Children Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Respiratory Syncytial Virus Vaccine for Children Production Mode & Process
- 9.2 Respiratory Syncytial Virus Vaccine for Children Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Respiratory Syncytial Virus Vaccine for Children Distributors
- 9.2.3 Respiratory Syncytial Virus Vaccine for Children Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst